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Galactagogues are substances thought to increase breast milk production, however evi-
dence to support their efficacy and safety remain limited. We undertook a survey among
Australian women to examine patterns of use of galactagogues and perceptions regarding
their safety and effectiveness.
Methods
An online, cross-sectional survey was distributed between September and December 2019
via national breastfeeding and preterm birth support organisations, and networks of several
research institutions in Australia. Women were eligible to participate if they lived in Australia
and were currently/previously breastfeeding. The survey included questions about galacta-
gogue use (including duration and timing), side effects and perceived effectiveness (on a
scale of 1 [Not at all effective] to 5 [Extremely effective]).
Results
Among 1876 respondents, 1120 (60%) reported using one or more galactagogues. Women
were 31.5 ± 4.8 years (mean ± standard deviation) at their most recent birth. Sixty-five per-
cent of women were currently breastfeeding at the time of the survey. The most commonly
reported galactagogues included lactation cookies (47%), brewer’s yeast (32%), fenugreek
(22%) and domperidone (19%). The mean duration of use for each galactagogue ranged
from 2 to 20 weeks. Approximately 1 in 6 women reported commencing galactagogues
within the first week postpartum. Most women reported receiving recommendations to use
herbal/dietary galactagogues from the internet (38%) or friends (25%), whereas pharmaceu-
tical galactagogues were most commonly prescribed by General Practitioners (72%). The
perceived effectiveness varied greatly across galactagogues. Perceived effectiveness was
highest for domperidone (mean rating of 3.3 compared with 2.0 to 3.0 among other
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galactagogues). Over 23% of domperidone users reported experiencing multiple side
effects, compared to an average of 3% of women taking herbal galactagogues.
Conclusions
This survey demonstrates that galactagogues use is common in Australia. Further research
is needed to generate robust evidence about galactagogues’ efficacy and safety to support
evidence-based strategies and improve breastfeeding outcomes.
Introduction
Breastfeeding is widely recognised to promote lifelong health for both the mother and infant
[1]. International recommendations are exclusive breastfeeding until six months of age, with
ongoing breastfeeding for two years or longer [2, 3]. In Australia, evidence indicates that the
majority of women initiate breastfeeding at birth; however, by six months of age, only 60% are
providing any breast milk, and 16% are exclusively breastfeeding [4]. This marked drop in
exclusive breastfeeding has been observed in many other high-income countries [5]. Previous
research shows that lactation insufficiency (also referred to as low breast milk supply), whether
real or perceived, is one of the most common reasons women discontinue breastfeeding [6, 7].
Lactation insufficiency can be caused by several factors, including insufficient mammary tis-
sue, irregular hormone levels, and ineffective milk removal from the breast [8].
The first-line management of lactation insufficiency involves non-pharmacological inter-
ventions, such as ensuring correct infant positioning and attachment [8, 9]. Where lactation
insufficiency persists, galactagogues—the term used to describe substances thought to promote
or increase breast milk production—may be used. Commonly reported galactagogues include
dietary or herbal supplements, for example, oats or fenugreek, and pharmaceutical treatments
such as domperidone [10]. Anecdotally, recent studies demonstrate widespread awareness and
use of there is increased promotion of dietary galactagogues such as lactation cookies [11, 12].
An examination of widely promoted recipes and commercially available products indicates
that lactation cookies contain highly variable combinations and quantities Internet searches
outline a variety of ingredients, including oats, brewer’s yeast and flaxseed.
A recent Cochrane review on the use of oral galactagogues for increasing breast milk pro-
duction in mothers of non-hospitalised term infants identified forty-one randomised clinical
trials [10]. The review found uncertain evidence that galactagogues improve breast milk vol-
ume or longer-term breastfeeding outcomes [10]. In contrast, several high-quality studies have
found domperidone effective in increasing breast milk production, specifically among mothers
of preterm infants [13, 14]. However, the use of domperidone remains controversial. Domper-
idone use at doses above 30 mg daily may present a risk of serious cardiac side effects [15].
However the relevance to breastfeeding women has been questioned as previous data on
increased cardiac risks mainly involved males and those aged over 60 years [16].
The considerable variation across studies concerning study population, intervention type,
and outcome evaluation has led to ongoing treatment uncertainties. This is reflected in the
recent guidelines issued by the Academy of Breastfeeding Medicine, which state that there is
insufficient evidence to recommend one galactagogue over another [17].
Despite conflicting evidence regarding the benefits of galactagogues in clinical practice,
there is evidence that breastfeeding women commonly use galactagogues, and use may be
increasing. For example, a 2012 Australian survey of 304 breastfeeding women observed that
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24% of respondents reported using a herbal galactagogue [18]. Estimates of uptake of the phar-
maceutical galactagogue domperidone appear more variable. Studies based on prescribing/dis-
pensing records from Australia, Canada and the UK show increasing trends in use, with
varying overall prevalence of use ranging from 2.7% to 20% [19–22]. In specific populations
such as following preterm birth, prevalence appears even higher, up to 30% [19, 21]. Further,
Grzeskowiak et al. examined queries relating to galactagogues at an Australian medicines
information centre from 2001 to 2014 that demonstrated a significant trend towards increased
phone calls regarding herbal galactagogues (0% to 23% of calls regarding galactagogues from
2001 to 2014) compared with a consistent interest in pharmaceutical galactagogues [23].
Unfortunately, the most recent studies evaluating galactagogue use only include data until
2015 and did not collect data on all types of galactagogues [12, 18–20]. Therefore, we sought to
undertake a survey to examine patterns of use of galactagogues, women’s experiences relating
to use, as well as their perceptions regarding effectiveness.
Methods
Ethics
This study was approved by the Human Research Ethics Committee at the University of Ade-
laide (approval number H-2019033934).
Survey administration
Women currently living in Australia and either currently breastfeeding or who had previously
breastfed were eligible to complete the survey. The survey was available online between 27 Sep-
tember 2019 and 12 December 2019. The survey consisted of part A, perceived safety and
knowledge of galactagogues, and part B, personal experiences and use of galactagogues, includ-
ing the self-perceived effectiveness, side effects and duration of use. If women had not taken
any galactagogues, they did not complete part B of the survey. This paper will focus predomi-
nantly on part B of the survey. Questions included in the survey covered the timing and dura-
tion of use of substances, sources of recommendation, side effects experienced and perceived
effectiveness. The perceived effectiveness of galactagogues was assessed using a 5-point Likert
scale from 1 (Not at all effective) to 5 (Extremely effective). The survey was tested for face
validity with two consumers and an academic breastfeeding expert. Only minor changes were
made to the survey before formal distribution through social networks (i.e. Facebook, Twitter,
email) of the Australian Breastfeeding Association [24, 25] (Australia’s national breastfeeding
support service, assisting more than 80,000 women each year, with over 1100 breastfeeding
counsellors available), Miracle Babies [26] (Australia’s leading organisation supporting prema-
ture and sick newborns, present in 143 Neonatal Intensive Care Units or Special Care Nurser-
ies in Australia), as well as research networks of the author’s respective institutions (e.g. The
Robinson Research Institute, and The University of Adelaide). Participants were encouraged
to share the survey and post links to the survey through their own social networks. The survey
was piloted with a small group of consumers (reviewed by representatives from the Australian
Breastfeeding Association and Miracle Babies) and academic experts in survey design, result-
ing in minor modifications before the final survey was launched. The complete survey is avail-
able as S1 File.
Study data were collected and managed using Research Electronic Data Capture (REDCap)
hosted at The University of Adelaide [27, 28]. REDCap is a secure, web-based software plat-
form designed to support data capture for research studies, providing 1) an intuitive interface
for validated data capture; 2) audit trails for tracking data manipulation and export proce-
dures; 3) automated export procedures for seamless data downloads to standard statistical
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packages, and 4) procedures for data integration and interoperability with external sources.
Only study investigators involved in the study had access to the data.
Completing the survey was voluntary, and no incentives were offered to participants.
Respondents had the opportunity to submit their responses anonymously or could choose to
include their contact details. When contact details were provided, respondents were
approached to participate in a separate qualitative study investigating women’s experiences of
using galactagogues. Only those who provided their contact details were able to withdraw their
responses, however none elected to withdraw their responses. A total of 2152 responses were
received, 7 responses were removed due to suspected duplicate entries based on identical
maternal characteristics provided in the entry section, and a further 90 were removed due to
births occurring outside of Australia.
Data analysis
Data were cleaned and analysed using STATA 14 (StataCorp LP, College Station, TX). Graphi-
cal images were produced using GraphPad Prism version 9 (GraphPad Software, La Jolla Cali-
fornia USA) and R Upset Package [29]. Maternal demographic characteristics and data on use
and experiences of galactagogues were described using descriptive statistics. The most com-
mon combinations of galactagogues used were graphed using an UpSet plot. Differences in
maternal characteristics according to any galactagogue use were compared using Student’s T-
test for means and Pearson’s Chi2 test for categorical variables. Duration of use was reported
separately for each galactagogue according to those that were continuing use at the time of the
survey and those that had stopped using it prior to completing the survey. Descriptive statistics
were used to report the means and standard deviations. Where data were non-normally dis-
tributed, the median and inter-quartile ranges were used. Statistical significance was defined as
a P< 0.05.
Results
A total of 1876 women responded to the survey. Maternal demographic characteristics of sur-
vey respondents are presented in Table 1. Briefly, the average age of women who responded
was 31.5 years old, while most had completed secondary schooling or higher (92%) and almost
half were primiparous (47%). At the time of the survey, 1217 (65%) of women reported they
were currently breastfeeding their infant. For women who reported currently breastfeeding,
the average infant age at the time of survey response was 10.7 months (mean ± 10 months stan-
dard deviation). Women who reported having ceased breastfeeding before completing the sur-
vey discontinued at an average of 21 months (mean ± 11 months standard deviation). Almost
half of all respondents (49%) felt they could not produce enough breast milk for their child,
and 63% sought help from a lactation consultant or breastfeeding expert. Of women who had
stopped breastfeeding prior to completing the survey (35%), 19% reported stopping due to low
milk supply.
Galactagogue use
Overall, 60% of women (n = 1120) reported taking one or more galactagogues during breast-
feeding. Women who had preterm births, saw a lactation consultant, were primiparous, had
perceived low milk supply, had a Caesarean section, or required supplemental feeding with
infant formula were more likely to use galactagogues (Table 1).
Information on individual galactagogue use is presented in Table 2. The most commonly
used galactagogue included lactation cookies (47%), brewer’s yeast (32%) and fenugreek
(22%). The use of ‘Other’ galactagogues were reported by 7.3% (n = 137) of women, which
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included oats (n = 87; 4.7%), malt products (n = 42; 2.2%), and flaxseed or linseed (n = 13;
0.7%).
With respect to domperidone and metoclopramide, which are only available by prescrip-
tion, these were most commonly prescribed by general practitioners (76% and 67% respec-
tively), followed by obstetricians/gynaecologists (20% and 10% respectively). For the
remaining galactagogues, the most common recommendation source was the internet (rang-
ing from 28–50%) and friends (ranging from 15–45%). Healthcare professionals such as com-
munity pharmacists (2–6%), general practitioners (2–7%), and obstetricians/gynaecologists
(1–2%) were uncommon sources of recommendation. One in three women taking herbal or
dietary galactagogues reported using two or more recommendation sources.
Among those reporting galactagogue use, 27% took only one substance, while 46% used three
or more galactagogues. The maximum number of galactagogues used was 10. The most common
patterns of galactagogue use are represented in Fig 1. Lactation cookies featured in the top five
different combinations of galactagogues used, and were the most used sole galactagogue.
Timing of commencement of galactagogues
Reported timing of commencement of galactagogue use is presented in Fig 2. Approximately
50% of galactagogues were commenced within the first four weeks postpartum, with 18.5%
Table 1. Maternal characteristics according to any reported use of a galactagogue during breastfeeding.
Total survey population Did not use galactagogue Used a galactagogue P-value�
n (%) n (%) n (%)
N (Total = 1876) 2055 756 1120
Mothers age at delivery (years; mean ± SD) 31.5 ± 4.8 32 ± 5.2 31.2 ± 4.5 <0.001
Youngest child’s age at survey 0.005
0–< 6 months 560 (30) 223 (30) 335 (30)
� 6–< 12 months 370 (20) 124 (17) 246 (22)
� 12 months 936 (50) 405 (54) 527 (48)
State/Territory of youngest child’s birth 0.291
Australian Capital Territory 88 (5) 40 (5) 48 (4)
New South Wales 453 (24) 192 (26) 259 (23)
Northern Territory 23 (1) 9 (1) 14 (1)
Queensland 322 (17) 111 (15) 210 (19)
South Australia 378 (20) 150 (20) 225 (20)
Tasmania 43 (2) 17 (2) 25 (2)
Victoria 407 (22) 176 (24) 231 (21)
Western Australia 150 (8) 55 (7) 94 (9)
Completed secondary school 1887 (92) 698 (93) 1027 (92) 0.834
Primiparous 882 (47) 255 (34) 625 (56) < 0.001
Multiple birth 39 (2) 14 (2) 25 (2) 0.578
Preterm birth 218 (12) 66 (9) 150 (14) 0.002
Caesarean-section 621 (33) 192 (26) 426 (38) <0.001
Perceived low milk supply 928 (49) 162 (22) 761 (68) <0.001
Saw a lactation consultant 1184 (63) 381 (51) 798 (71) <0.001
Supplemented with infant formula 561 (30) 111 (15) 446 (40) <0.001
Any smoking during breastfeeding 66 (4) 23 (3) 43 (4) 0.358
� Chi2 test between those that used and did not use a galactagogue.
https://doi.org/10.1371/journal.pone.0254049.t001
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Table 2. Reported use of galactagogues and information sources from breastfeeding women (n = 1876).












355 (19) 21 (1) 421 (22) 98 (5) 157 (8) 40 (2) 52 (3) 592 (32) 884 (47) 109 (6)
Mothers age at birth
(years; mean ± SD)
31.8 ± 4.6 34.1 ± 4.2 31.7 ± 4.4 31.7 ± 4.3 31.5 ± 4.5 31.5 ± 4.5 31.2 ± 4.9 30.9 ±4.4 31 ± 4.4 32.1 ± 4.4
Child’s age at survey�
0–6 months 110 (31) 2 (10) 105 (25) 29 (30) 44 (28) 13 (33) 19 (37) 158 (27) 264 (30) 42 (39)
6–12 months 79 (22) 4 (19) 86 (21) 18 (18) 43 (28) 8 (20) 16 (31) 135 (23) 210 (24) 23 (21)
12+ months 163 (46) 15 (71) 227 (54) 51 (52) 68 (44) 19 (48) 16 (31) 292 (50) 401 (46) 43 (40)
Maternal characteristics �
Primiparous 208 (59) 7 (33) 238 (57) 49 (50) 91 (58) 19 (48) 28 (54) 332 (56) 528 (60) 60 (55)
Preterm birth 74 (21) 7 (33) 70 (17) 17 (17) 22 (14) 9 (23) 7 (13) 85 (14) 125 (14) 14 (13)
Caesarean section 162 (46) 14 (67) 157 (37) 33 (34) 61 (39) 18 (45) 25 (48) 207 (35) 328 (37) 46 (42)
Perceived low milk
supply
327 (92) 19 (90) 331 (79) 88 (90) 114 (73) 34 (85) 40 (77) 423 (71) 619 (70) 72 (66)
Took only this
substance �




57 (16) 1 (5) 168 (40) 34 (35) 43 (27) 15 (38) 14 (27) 272 (46) 421 (48) 27 (25)
Who prescribed/recommended �
General Practitioner 271 (76) 14 (67) 30 (7) 5 (5) 3 (2) 1 (3) 3 (6) 22 (4) 21 (2) 2 (2)
Obstetrician/
Gynaecologist
72 (20) 2 (10) 7 (2) 1 (1) 1 (1) 1 (2) 4 (1) 8 (1)
Midwife 41 (12) 2 (10) 67 (16) 14 (14) 8 (5) 3 (8) 3 (6) 65 (11) 87 (10) 6 (6)
Neonatologist/
paediatrician
19 (5) 2 (10) 9 (2) 2 (2) 1 (0) 4 (0) 1 (1)
Internet search 119 (28) 30 (31) 54 (34) 20 (50) 17 (33) 278 (47) 356 (40) 34 (31)
Lactation consultant 90 (21) 26 (27) 18 (11) 6 (15) 3 (6) 76 (13) 117 (13) 9 (8)
Friends 87 (21) 15 (15) 28 (18) 11 (28) 12 (23) 211 (36) 395 (45) 26 (24)
Family 58 (14) 9 (9) 25 (16) 5 (13) 16 (31) 98 (17) 174 (20) 14 (13)
Child & family health
nurse
45 (11) 8 (8) 5 (3) 2 (5) 1 (2) 35 (6) 60 (7)
Naturopath 40 (10) 14 (14) 29 (18) 8 (20) 7 (13) 23 (4) 17 (2) 16 (15)
Neonatal nurse 36 (9) 5 (5) 7 (4) 4 (10) 3 (6) 30 (5) 54 (6) 1 (1)
Mother’s group 33 (8) 4 (4) 11 (7) 2 (5) 4 (8) 56 (9) 112 (13) 4 (4)
Social media 34 (8) 5 (5) 11 (7) 3 (8) 5 (10) 91 (15) 160 (18) 11 (10)
Blogs or online
discussion forums
24 (6) 4 (4) 6 (4) 1 (3) 5 (10) 56 (9) 77 (9) 4 (4)
Community
pharmacist
24 (6) 4 (4) 4 (3) 18 (3) 15 (2) 5 (5)
Breastfeeding helpline 10 (2) 2 (1) 1 (2) 12 (2) 20 (2) 2 (2)
Books 6 (1) 1 (1) 3 (2) 8 (1) 7 (1) 2 (2)
Podcasts 1 (0) 1 (2) 1 (0) 3 (0) 1 (1)
Other 15 (4) 2 (10) 18 (4) 7 (7) 14 (9) 3 (8) 1 (2) 21 (4) 44 (5) 14 (13)
� (n (% of those who took each galactagogue)).
https://doi.org/10.1371/journal.pone.0254049.t002
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commenced within the first seven days. Timing of commencement varied considerably
according to the individual type of galactagogue used. The proportion of women reporting
commencing individual galactagogues within the first seven days postpartum, ranged from 4
to 67%.
Effectiveness
The perceived effectiveness of galactagogues is reported in Fig 3. The mean perceived effective-
ness for eight of nine galactagogues was rated as being between ’slightly’ (2) and ’moderately’
(3) effective (Fig 3), except for domperidone which users reported as having the highest per-
ceived effectiveness (3.3 ± 1.2; mean ± standard deviation).
Side effects
Side effects women experienced according to galactagogue use are presented in Table 3. Dom-
peridone had the highest proportion of women reporting one or more side effects (45%), com-
pared to less than 20% of women using herbal galactagogues. For domperidone and
metoclopramide, 9% and 19% of women respectively stopped taking the medication due to
side effects. Greater than 20% of domperidone users experienced two or more side effects.
Fig 1. UpSet plot showing the use of different galactagogues and combinations thereof in breastfeeding women (n = 1120).
https://doi.org/10.1371/journal.pone.0254049.g001
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Duration of use
The median reported duration of use for each galactagogue is presented in Fig 4. Overall, the
median reported duration of use was longer in women who were currently taking a galactago-
gue at the time of the survey completion. Median durations of use varied from 2 (ginger) to 7
(combination of herbs) weeks for those who had stopped using a substance, and 6 (milk this-
tle) to 19 weeks (ginger) for those who were continuing use at the time of the survey.
Recommendations
The percentages of women who would recommend a particular galactagogue to a friend is pre-
sented in Fig 5. Overall, 75% would recommend a galactagogue to a friend. There appeared to
be a strong correlation between the perceived effectiveness of a galactagogue and whether or
not women would recommend it to a friend. Of the 25% of women who would not recom-
mend to a friend, 71% indicated a perceived lack of effectiveness as a reason.
Fig 2. Timing of commencement postpartum of galactagogues during breastfeeding.
https://doi.org/10.1371/journal.pone.0254049.g002
Fig 3. Perceived effectiveness of galactagogues used by women who were breastfeeding (n = 1120).
https://doi.org/10.1371/journal.pone.0254049.g003
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Discussion
In this large contemporary survey of Australian women, galactagogue use was reported by
60% of women at some stage during their lactation. Women commonly reported using multi-
ple galactagogues, with median durations of use from 2–19 weeks or more and 50% of galacta-
gogues being commenced within the first four weeks postpartum. Galactagogues appeared to
be well tolerated, except for pharmaceutical galactagogues, where side effects were reported by
approximately 50% of women. The widespread utilisation and experiences of galactagogues in
postpartum women highlights the importance of future research aimed at (a) understanding
why women are using them in the face of limited evidence and guidance about their use, and
(b) improving evidence regarding the efficacy and safety of individual galactagogues to support
informed decision making.
The need to develop additional strategies to support breastfeeding mothers is reflected in
nearly half of our sample reporting that they felt they could not produce enough milk for their
child at some stage, with almost 1 in 5 women discontinuing breastfeeding due to concerns
about their milk supply. It is uncertain whether concerns related to breast milk supply were
real or perceived, determining which has been often recognised as a common challenge within
clinical practice settings [6]. The high proportion of women reporting concerns about their
breast milk production in our study (approximately 50%) is consistent with previous studies
from Australia (45%) and the United States (76%) [12, 30].
Table 3. Self-reported side effects for galactagogues used by breastfeeding women (n = 1120).










Took substance (N) 355 21 421 98 157 40 52 592 884 109
Any side effects � 159 (45) 6 (29) 72 (17) 8 (8) 7 (4) 4 (10) 3 (6) 65 (11) 110 (12) 5 (5)
Two or more side
effects�
80 (23) 5 (24) 22 (5) 4 (4) 3 (2) 3 (8) 1 (2) 12 (2) 15 (2) 0 (0)
Individual side effects�
Weight gain 88 (25) 2 (10) 10 (2) 1 (1) 2 (5) 1 (2) 20 (3) 79 (9) 1 (1)
Headache 59 (17) 3 (14) 9 (2) 1 (1) 1 (3) 1 (2) 4 (1) 4 (0) 1 (1)
Dry mouth 47 (13) 3 (14) 11 (3) 2 (2) 1 (1) 2 (5) 1 (2) 9 (2) 11 (1) 1 (1)
Fatigue 31 (9) 3 (14) 4 (1) 2 (2) 6 (1)
Irritability 22 (6) 3 (14) 2 (0) 1 (3) 3 (1) 4 (0) 1 (1)
Depression 20 (6) 2 (10) 3 (1) 3 (1) 3 (0)
Stomach cramps 14 (4) 17 (4) 3 (3) 3 (2) 16 (3) 13 (1)
Nausea 13 (4) 3 (14) 11 (3) 3 (3) 4 (3) 1 (3) 1 (2) 11 (2) 4 (0)
Heart palpitations
/racing heart
13 (4) 3 (14) 3 (1) 2 (0) 2 (0)
Dizziness /fainting 12 (3) 5 (1) 1 (1) 1 (3) 4 (1) 5 (1)
Involuntary
movements /jerking
4 (1) 2 (10)
Skin rash 2 (1) 2 (0) 1 (0) 1 (0)
Other 12 (3) 14 (3) 1 (1) 2 (1) 7 (1) 12 (1) 1 (1)
Body odour 11 (3)
Decreased supply 6 (1)
Gas/bloating 8 (1)
� n (% of those who took each galactagogue).
https://doi.org/10.1371/journal.pone.0254049.t003
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Our data showed that women were more likely to take a galactagogue based on several preg-
nancy/birth characteristics such as primiparity, preterm birth or caesarean delivery, as well as
perceived low breast milk supply. These risk factors are consistent with those previously
reported in the literature, and commonly associated with breastfeeding difficulties [8, 22, 31].
Fig 4. Duration of galactagogue use by women who had (a) stopped use and those who are (b) continuing use at the time of survey completion
(median, inter-quartile range, and 5th to 95th percentile whiskers).
https://doi.org/10.1371/journal.pone.0254049.g004
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A previous 2012 survey of women in Western Australia found that 24% of 304 respondents
reported using a herbal galactagogue during breastfeeding [18]. The most common galactago-
gues included fenugreek (18%), blessed thistle (6%) and fennel (5%) [18]. In comparison, a
2015 US survey of 188 women reported herbal galactagogue use in 46% of respondents [12].
The most common galactagogues were fenugreek (46%), fennel (16%) and milk thistle (13%)
[12]. However, the survey was restricted to women who reported using or intending to use
galactagogues. Notably, neither of these studies collected data regarding the use of the dietary
galactagogues lactation cookies or brewer’s yeast which were the most commonly reported
galactagogues in our survey. Regarding the use of herbal galactagogues, we observed similar
high usage of fenugreek, and lower but notable use of fennel [12]. The number of women
reporting using domperidone in our survey (1 in 5 respondents) was higher than initially
anticipated. A previous Australian audit of domperidone use in the postpartum period at a sin-
gle tertiary maternity teaching hospital from 2000 to 2010 reported a prevalence of 5% [19].
However, as the audit was restricted to domperidone supplied from the hospital pharmacy
department, it likely represents an underestimation of total use [19]. By comparison, interna-
tional studies evaluating domperidone use from 2011 to 2015 have produced widely varying
prevalence ranging from 2% in the UK [20] 2.7% in the US [12], and 20% in Canada [21].
Among high-risk subgroups, such as women with preterm birth, the prevalence of domperi-
done use increased to 30% [19, 21]. Such differences may reflect differences in inter-country
domperidone availability, clinical practice guidelines and prescriber/consumer awareness.
Domperidone had the highest perceived effectiveness rating but also had the highest pro-
portion of women reporting side effects. While previous meta-analyses provide moderate-
quality evidence to support the use of domperidone in managing lactation insufficiency fol-
lowing preterm birth [13], there is no such equivalent evidence that it is effective in mothers of
otherwise healthy term infants [10]. This represents a significant evidence-gap given wide-
spread uptake of domperidone use following term birth.
While fenugreek was the most commonly used herbal galactagogue and appeared to be
well-tolerated, a recent meta-analysis demonstrated that it seems to be no more effective than
a placebo in treating lactation insufficiency [10, 32].
Fig 5. Women’s recommendations of galactagogues to a friend and their reasons for not recommending.
https://doi.org/10.1371/journal.pone.0254049.g005
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The observation that a high proportion of women are taking galactagogues based on recom-
mendations from the internet is consistent with a 2015 survey conducted in the United States
demonstrated that 48% of women taking fenugreek sourced their information online. The
same study also found that up to 85% of women sought information from sources other than
their primary care provider or lactation consultants [12]. Frequent use of information sources
other than healthcare professionals raises concerns regarding whether or not women are being
provided with evidence-based information regarding the use of galactagogues to support
informed decision making. This is backed up by findings from an Australian survey of wom-
en’s attitudes to herbal medicine during lactation that found that while the internet was again
a common source of information, women often doubted the reliability of information from
the internet and cited the need for information and resources endorsed by reputable breast-
feeding organisations and healthcare professionals [30, 33]. The second highest source of
information was women’s friends, which may suggest that women prioritise others’ anecdotal
experiences over that of evidence-based resources or trained health care professionals.
The fact that 1 in 6 respondents started using various galactagogues within the first seven
days postpartum raises potential concerns, particularly given the challenge of assessing the
adequacy of breast milk production in the early postpartum period [34, 35]. These findings
may indicate that women may be turning to galactagogues prophylactically (without actually
having low breast milk supply) or using them as early treatments before trying non-pharmaco-
logical strategies. While 71% of women reported seeing a lactation consultant, we do not know
when this occurred relative to the commencement of galactagogues. The observation that 20%
of galactagogue use occurred after three months postpartum highlights the importance of con-
tinued breastfeeding support beyond the immediate postpartum period.
Strengths and limitations
This survey is the first to examine galactagogue use, the timing and duration of use, as well as
perceived effectiveness and side effects of common galactagogues in the community. This
study has several limitations. Our survey used non-probabilistic sampling and snowballing
sampling techniques, making it difficult to extrapolate findings to the broader Australian pop-
ulation of breastfeeding women. Based on national Australian perinatal statistics, while our
survey included a higher proportion of women born in Australia (86% vs 65%), the distribu-
tion of other key demographic and birth characteristics known to influence breastfeeding out-
comes such as maternal age at delivery (31.5 years vs. 30.4 years), delivery by caesarean section
(33% vs. 35%), preterm birth (12% vs. 9%), and prevalence of overweight/obese (49% vs 45%),
were similar [36].
The survey measured women’s perceived effectiveness and did not utilise objective mea-
sures of changes in breast milk supply. The support and clinical care women received during
breastfeeding were also not reported, meaning some women’s perceived increase in supply
may have been unrelated to galactagogue use.
Lactation cookies were provided as one of ten listed galactagogues that women could
choose from. However participants were not provided with a definition of lactation cookies
nor a pre-defined list of ingredients. As such, our survey did not account for possible varia-
tions in ingredients between different lactation cookies, and there is likely to be some crossover
with other galactagogues listed in the survey, particularly brewer’s yeast which is one of the
most common ingredients in lactation cookies. While 1217 women were breastfeeding at the
time of the survey, responses were obtained from 657 women who had completed breastfeed-
ing up to an average of 3.9 years before completing the survey. This raises the possibility of
errors related to women’s ability to recall exact timings and durations of use correctly.
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However, previous studies suggest the degree of error is likely to be small, with a 1-month
error in reporting among women recalling information from 1 to 3.5 years prior [37]. Further-
more, for women continuing to breastfeed and taking a galactagogue at the time of completing
the survey, it is not possible to correctly define the total duration of use or their complete set of
experiences. Lastly, we did not ask about galactagogue use before birth. Some women use
herbal galactagogues before birth to stimulate lactation initiation, which is of concern as some
popular herbal galactagogues such as fenugreek and milk thistle may cause uterine contrac-
tions [38].
Concluding remarks
This large online survey demonstrates that the use of galactagogues appears to be very com-
mon in Australia. Women seem to be using multiple galactagogues during breastfeeding, with
evidence of frequent initiation in the first week postpartum and long durations of use. The
incidence of side effects appeared higher for women taking pharmaceutical agents compared
to herbal galactagogues. However, a number of side effects were still reported by women using
herbal or food-based galactagogues, suggesting they are not completely benign. The high prev-
alence of women taking galactagogues based on recommendations obtained through the inter-
net or friends, rather than healthcare providers, raises concerns surrounding the potential
quality of the information they receive, particularly in light of the lack of evidence surrounding
the effectiveness and safety of most galactagogues. Overall, our findings highlight the need for
further high-quality research, particularly appropriately powered randomized controlled trials,
to generate robust evidence about the efficacy and safety of galactagogues to support evidence-
based strategies to improve breastfeeding outcomes.
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